<DOC>
	<DOC>NCT02612259</DOC>
	<brief_summary>A phase II, randomized, double-blind, placebo-controlled, in parallel groups clinical trial to assess the safety and efficacy of dietary supplementation with tryptophan to achieve weight loss, and its neuropsychological effects in adolescents with obesity.</brief_summary>
	<brief_title>A Phase II, Randomized, Double-blind, Placebo-controlled, in Parallel Groups Clinical Trial to Assess the Safety and Efficacy of Dietary Supplementation With Tryptophan to Achieve Weight Loss, and Its Neuropsychological Effects in Adolescents With Obesity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Tryptophan</mesh_term>
	<criteria>1. Both male and female patients, attending the Pediatric Endocrinology Service on an outpatient basis. 2. Age from 12 to 17 years, inclusively. 3. Presence of a BMI &gt; or = to 2SD and &lt; or = to 4SD (standard deviations) for their age and sex (Spanish crosssectional growth reference tables of 2008) 4. Patients must have an educational level that permits adequate communication and must agree to cooperate in all the tests and examinations included in the protocol. 5. Subjects of reproductive potential must use an effective birth control method during the study. Women of reproductive age will be recruited after a negative pregnancy test. 6. The informed consent of the parents or legal representative and of the young adults is required. 1. Obesity secondary to an endocrine disease (hypothyroidism, Cushing?s syndrome, polycystic ovary, hypothalamic syndromes, hypogonadism) or the use of medications such as cortisol. 2. Concomitant administration of other psychotrophic medication such as antidepressants or anxiolytics. 3. Patients included in the study must not be taking any vitamins or nutritional supplements or any antiobesity preparations, including herbal remedies, pharmacy products or homeopathic products. 4. Patients with a known psychiatric disorder. 5. Patients treated with any kind of structured psychotherapy regime. 6. Patients with type 2 DM, arterial hypertension (blood pressure above the 95 percentile for gender and height) or steatotic liver (hypertransaminasemia with echographic image of fatty liver). 7. Patients with any severe food intolerance, or with a known allergy to any of the substances used in the study. 8. Patients in treatment with oral hypoglycemiants. 9. Pregnant or breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>